# Metabolic Peptide FAQ — Retatrutide, MOTS-c, Tesamorelin — Freebase Peptides

> Frequently asked questions about three Metabolic & Weight Research peptides — retatrutide, MOTS-c, and tesamorelin — answered from the peer-reviewed literature, with citations.

Concise, citation-anchored answers to the questions readers most often bring to these three metabolic research peptides.

## What does retatrutide do?

In clinical trials, retatrutide acts as a simultaneous agonist at three hormone receptors: GIP, GLP-1, and glucagon. The GLP-1 and GIP arms suppress appetite and improve glucose-dependent insulin secretion; the glucagon arm adds thermogenic energy expenditure and lipid mobilization [1]. The net result in Phase 2 studies was a mean body-weight reduction of approximately 24% over 48 weeks in adults with obesity [4] and a 16.94% weight reduction in a 36-week type 2 diabetes trial [5]. All of this is from supervised clinical trials; these are not general-use outcomes, and retatrutide is not an approved drug.

## How does retatrutide work?

Retatrutide binds and activates three receptors — GIP receptor (GIPR), GLP-1 receptor (GLP-1R), and glucagon receptor (GCGR) — on a single molecule. Cryo-EM structures have resolved how it engages all three receptor complexes [2]. The GLP-1 and GIP components suppress food intake and slow gastric emptying; the partial glucagon agonism drives a thermogenic response that increases energy expenditure. This triple action is believed to explain why Phase 2 weight-loss results exceed what dual or single agonists have achieved [1]. Its approximately 6-day half-life, derived from C20 fatty-acid acylation, supports once-weekly dosing [6].

## How to reconstitute retatrutide?

This desk is a literature digest and does not provide preparation or handling instructions for any compound. Reconstitution protocols for injectable peptides are clinical procedures conducted under sterile conditions by qualified personnel in appropriate research settings. Retatrutide is an investigational compound that is not available as an approved consumer product; describing preparation for unsupervised use falls outside this desk's scope. For study-protocol information, the TRIUMPH Phase 3 trial registrations (NCT05929066 and related) are publicly accessible on ClinicalTrials.gov.

## Is retatrutide FDA approved?

No. As of mid-2026, retatrutide is not approved by the FDA or any regulatory agency. It remains in Phase 3 clinical trials (the TRIUMPH program) conducted by Eli Lilly. Phase 2 data have been published [4][5], but Phase 3 completion and a New Drug Application submission and approval process have not yet occurred. All retatrutide efficacy and safety figures on this site come from clinical trial publications, not from approved labeling. Material sold through gray-market research channels is not subject to pharmaceutical-grade identity or purity verification [1].

## What does the MOTS-c peptide do?

MOTS-c is a 16-amino-acid mitochondrially-encoded peptide. Its best-characterized metabolic action is inhibiting the folate cycle inside skeletal muscle cells, which raises AICAR and activates AMPK — the cellular energy sensor that improves glucose uptake and insulin sensitivity independent of insulin itself [10]. It also translocates to the nucleus under metabolic stress and regulates antioxidant and metabolic gene expression via NRF2 [12]. In animal studies, exogenous MOTS-c enhanced physical performance in aged mice and is described as an exercise-mimetic [11]. No human efficacy trials have been completed; all metabolic and performance claims derive from cell and animal work.

## What are the negative side effects of MOTS-c?

There are no published human safety trials of MOTS-c, so a clinical side-effect profile does not exist. The cautions documented in the literature are: (1) no validated human pharmacokinetics — rodent doses cannot be extrapolated; (2) ancestry-dependent and genotype-dependent responses have been identified, with a pro-diabetogenic mtDNA variant (m.1382A>C) documented in some populations [10]; (3) as an unapproved research chemical, purity, identity, and sterility of commercially available material are not regulated; and (4) MOTS-c is prohibited in competitive sport under WADA anti-doping rules. The absence of reported side effects in the literature reflects the absence of human trials, not confirmed safety.

## Is MOTS-c legal to buy?

In most jurisdictions, purchasing MOTS-c as a research chemical is not explicitly prohibited by statute, but the relevant legal and regulatory context has multiple layers. MOTS-c is not an approved drug; sellers market it for laboratory research use only. It is prohibited in competitive sport by WADA and enforcement bodies such as USADA; athletes subject to anti-doping rules face sanctions for use regardless of how it was acquired. Import and possession rules vary by country. Nothing on this desk constitutes legal advice; anyone considering research-chemical acquisition should consult the applicable jurisdiction's drug and chemical import regulations.

## How often do you inject MOTS-c?

This desk does not provide dosing or administration schedules for any compound. MOTS-c has no validated human pharmacokinetics, and there is no peer-reviewed dose-frequency guidance for human use. The animal studies used a range of protocols that cannot be directly applied to humans [10][11]. Any dosing protocol circulating in research communities lacks a clinical-trial basis. If a legitimate research purpose exists, appropriate study design and institutional review apply.

## What is tesamorelin?

Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH), with a trans-3-hexenoic acid group on its N-terminus that resists enzymatic degradation [14]. It is FDA-approved (NDA 022505, 2010) to reduce excess abdominal fat in HIV-infected adults with antiretroviral-related lipodystrophy. Outside that indication, all uses are off-label and investigational. It works by binding the GHRH receptor on pituitary cells, stimulating the body's own pulsatile growth-hormone secretion, which then drives preferential lipolysis in visceral fat via the GH/IGF-1 axis.

## What does tesamorelin do?

In its approved indication, tesamorelin reduces excess visceral (abdominal) fat in HIV-infected adults with lipodystrophy. A 2026 meta-analysis of five RCTs found a mean visceral adipose tissue reduction of 27.71 cm² and a mean lean body mass increase of 1.42 kg, alongside reductions in trunk fat (-1.18 kg) and hepatic fat fraction (-4.28%), all without serious adverse events [13]. In a JAMA randomized trial, visceral fat was reduced by 42 cm² (P=0.005) and hepatic fat by 2.9% (P=0.003) at 6 months [15]. The effect requires continued dosing — VAT reaccumulates after discontinuation [17].

## How does tesamorelin work?

Tesamorelin binds the GHRH receptor (GHRH-R) on anterior-pituitary somatotroph cells, activating Gs/adenylyl-cyclase/cAMP/PKA signaling. This stimulates the pituitary's own endogenous growth hormone synthesis and release in a pulsatile pattern. The resulting GH drives hepatic production of IGF-1. Together, GH and IGF-1 promote lipolysis preferentially in visceral adipose tissue [16]. The preserved pulsatility differentiates it from continuous recombinant GH administration and is associated with maintained insulin sensitivity in healthy subjects [16].

## Will tesamorelin help me lose belly fat?

The clinical evidence for visceral fat reduction is real but population-specific. Tesamorelin's RCT data consistently show significant VAT reductions — a mean of -27.71 cm² across five trials — in HIV-infected adults with lipodystrophy [13]. Whether the same effect size applies to individuals without HIV-associated lipodystrophy has not been established by large controlled trials [13]. Off-label use in non-HIV populations is investigational. Additionally, VAT reaccumulates upon discontinuation [17], meaning any effect is not permanent after stopping. This desk reports the research record and does not advise on use; consult a licensed clinician for individual guidance.

---

A clinical briefing on metabolic research peptides — peer-reviewed citations, stated approval status, no doses and no products.